The latest biotech news

News and Trends 20 Oct 2022

Sunshine Biopharma acquires Nora Pharma

Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Spanish research institution to use Elicera Therapeutics’ iTANK platform

Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Partnership formed to make drug for MoCD Type A available sooner

Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […]

October 20, 2022 - 2 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

C4XD and HitGen to collaborate on inflammation hit identification project

Drug discovery company C4X Discovery Holdings plc and HitGen Inc., which develops DNA-encoded library (DEL) technology, are to collaborate on identifying novel, small molecule hits against an inflammatory target for further C4XD development. The aim of the project is to augment C4XD’s pipeline of small molecule inflammatory disease candidates for pre-clinical development and out-licensing to […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

The role of long-read sequencing in validating CRISPR outcomes

Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of microbial, plant and gene therapy increasingly being realised, enthusiasm from the research community for this technology is not expected to wane. It has the potential to, among other applications, create knock-out animal models for use in research, revolutionise agriculture and […]

October 20, 2022 - 3 minutesmins - By External Contributor

News and Trends 20 Oct 2022

Enhanc3D Genomics raises £10M to advance technology platform

Enhanc3D Genomics, a functional genomics company, has raised £10 million ($11.2 million) in series A financing. The funds will be used to accelerate the development of its proprietary technology platform – GenLink3D. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures. The funding will enable Enhanc3D […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

VectorBuilder raises funds for gene delivery R&D

VectorBuilder Biotechnology (Guangzhou) Co., Ltd., a gene delivery enterprise, has completed a series C round with CNY410 million ($56.7 million). The funding was co-led by Legend Capital. The proceeds will help VectorBuilder promote the upgrading and capacity expansion of its gene delivery R&D and production technology platform, further accelerate its global business presence, and boost […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

License from Helmholtz Munich will enable progression of brain cancer treatment

A treatment for one of the most aggressive and difficult to treat cancers is the focus of a licensing option that has been executed by Isotope Technologies Munich SE (ITM). The license from Helmholtz Munich was announced yesterday (October 19). The targeted radionuclide therapy with ITM-31 targets a specific protein (antigen) called CA XII, which […]

October 20, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Sunshine Biopharma acquires Nora Pharma

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Spanish research institution to use Elicera Therapeutics’ iTANK platform

AbbVie acquires LifeArc portfolio company DJS Antibodies

Partnership formed to make drug for MoCD Type A available sooner

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

C4XD and HitGen to collaborate on inflammation hit identification project

The role of long-read sequencing in validating CRISPR outcomes

Enhanc3D Genomics raises £10M to advance technology platform

VectorBuilder raises funds for gene delivery R&D

License from Helmholtz Munich will enable progression of brain cancer treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!